AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04333303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of a complex regional Advance Care Planning program
Description: Sustainable implementation of ACP at micro- (qualification of professional ACP facilitators to lead conversations in cooperation with family physicians), meso- (qualification of relevant co-actors, organisational development of participating institutions) and macro-level (regional ACP steering group and network), ensuring that valid ACP is encouraged, facilitated, documented, known and honored.~Core of the intervention is a modular 9-day-training for ACP facilitators. These will be preferably located in regional pools, serving more than one nursing home, and reimbursed, if certified, by German sickness funds based on recent legislation (§ 132g Social Code Book \[SGB\] V: 1 full-time facilitator for 400 residents). ACP conversations will be offered to all residents. Regional intervention at meso- and macro-level comprises various formats of specific ACP training and information for leadership and staff, and aims to support professional change management.
Study NCT04486001 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSC-04
Description: adipose stem cells derived from screened donor lipoaspirate and culture expanded.
Study NCT04609007 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Description: A brief 4 sessions online CBT program with therapist support.
Study NCT04609007 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular help-line telephone counselling
Description: A single session of telephone counselling with a help-line counsellor
Study NCT02423967 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplant uses frozen anonymous stool
Description: The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
Study NCT02423967 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Transplant uses fresh familial stool
Description: The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
Study NCT00648050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride Extended-Release Capsules, 300 mg
Description: 300mg, single dose fasting
Study NCT00648050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verelan® PM Extended-Release Capsules, 300 mg
Description: 300mg, single dose fasting
Study NCT00770575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and atorvastatin
Description: Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.
Study NCT00770575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.
Study NCT00107640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-provider education
Description: Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
Study NCT02809716 — intervention group
Intervention type: OTHER
Intervention: Biomarker Analysis
Description: Correlative studies
Study NCT03884465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled dry powder treprostinil (LIQ861)
Description: Inhaled dry powder treprostinil (LIQ861) at 25μg, 50μg, 75μg, or 100μg capsule strengths. Single dose in the acute setting. QID in the chronic setting.
Study NCT02809716 — intervention group
Intervention type: OTHER
Intervention: Cytology Specimen Collection Procedure
Description: Undergo collection of blood and tissue samples
Study NCT02447224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 gm IV ertapenem at enrollment
Study NCT02447224 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 gm IV ertapenem at enrollment
Study NCT02447224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days
Study NCT02447224 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Appendectomy
Study NCT02720107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fingolimod
Study NCT02649348 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: pre-operative prehabilitation
Description: To climb six flights of stairs (approximately 20 meters in height) at least 6 times as a daily routine and adaptive simulated training of restrictive ventilation dysfunction (increased thoracic and decreased abdominal breathing compliance) following abdominal surgery by using a full elastic breathable abdominal bandage.
Study NCT00748852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTT-302
Description: JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
Study NCT01677429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR movie + balance challenge
Description: Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
Study NCT01677429 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: still pictures from VR
Description: Monitoring only still pictures from the VR scene in a loop, no balance challenge
Study NCT01677429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: For the treatment of panic disorder
Study NCT03719534 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: haplo-HCT
Description: HCT will be performed with a haploidentical donor
Study NCT03719534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: haplo-cord HCT
Description: Haploidentical donor HCT will be performed with coinfusion of unrelated cord blood unit
Study NCT02300636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
Study NCT02300636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Co-contraction training at 60 knee flexion angle by using leg press machine
Study NCT02300636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: Standard ACL rehabilitation
Study NCT02672696 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FluoroMap 3D
Description: Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
Study NCT04468529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Neuregulin for injection
Description: 10 hours per day i.v. drip for the first 10 days (0.6ug/kg/day)
Study NCT04468529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 hours per day i.v. drip for the first 10 days (0ug/kg/day)
Study NCT03459391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221 60 mg
Description: The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
Study NCT03459391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XC221 200 mg
Description: The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
Study NCT03459391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volunteers received the study drug once, and then continued daily intake for 5 days after a 6-day break.
Study NCT01945710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin-LF
Study NCT01771809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75mg SHP647 (PF-00547659)
Description: 75 mg sterile liquid injected subcutaneously every 4 weeks.
Study NCT01771809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 225mg SHP647 (PF-00547659)
Description: 225 mg sterile liquid injected subcutaneously every 4 weeks.
Study NCT03800394 — intervention group
Intervention type: OTHER
Intervention: Observational PK study
Description: Effect of antituberculosis treatment, age and genetic factors on intracellular TFV-DP and FTC-TP concentrations
Study NCT02856191 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Holter
Study NCT01800175 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Punctum Plug
Study NCT00727441 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX pancreatic cancer vaccine
Description: Given intradermally
Study NCT00727441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV (Arm B), given orally (Arm C)
Study NCT03038477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
Study NCT04992702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animated Video
Description: Animated video to improve learning and motivation
Study NCT04313647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1X level of MSCs-Exo
Description: Once aerosol inhalation of MSCs-derived exosomes (2.0\*10\^8 nano vesicles/3 ml)
Study NCT04313647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2X level of MSCs-Exo
Description: Once aerosol inhalation of MSCs-derived exosomes (4.0\*10\^8 nano vesicles/3 ml)
Study NCT04313647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4X level of MSCs-Exo
Description: Once aerosol inhalation of MSCs-derived exosomes (8.0\*10\^8 nano vesicles/3 ml)
Study NCT04313647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6X level of MSCs-Exo
Description: Once aerosol inhalation of MSCs-derived exosomes (12.0\*10\^8 nano vesicles/3 ml)
Study NCT04313647 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8X level of MSCs-Exo
Description: Once aerosol inhalation of MSCs-derived exosomes (16.0\*10\^8 nano vesicles/3 ml)
Study NCT04992702 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Animated Video
Description: Animated video to improve learning and motivation
Study NCT04992702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animated Video
Description: Animated video to improve learning and motivation
Study NCT04124744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Champions intervention
Description: Health Champions are trained volunteers who will support service users with their physical health goals over 9 months, meeting once a week
Study NCT04124744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group-treatment as usual
Description: Participants will receive treatment as usual from their Community Mental Health Team
Study NCT03939013 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Xpert HCV VL
Description: Use of Cepheid GeneXpert HCV VL test as diagnostic tool to test for HCV RNA for diagnosis of hepatitis C infection, to test for sustained virological response at 12 weeks post treatment completion
Study NCT00256295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg/m2 IV over 100 minutes Every 21 days
Study NCT00256295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days
Study NCT02027129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High Frequency Oscillation
Description: Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
Study NCT02176746 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cancer stem cell vaccine
Study NCT02176746 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: cancer stem cell vaccine
Study NCT03663556 — intervention group
Intervention type: OTHER
Intervention: Infant-feeding
Description: Preterm infants hospitalized in the NICU can be feed by three different types of infant feeding, such as breast milk, donor human milk and/or formulas.
Study NCT00940667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Losartan
Description: amlodipine/losartan 5/50mg q.d.
Study NCT00940667 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: amlodipine 5mg q.d.
Study NCT02811627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.
Study NCT02811627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
Study NCT02110602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet high in amino acid levels
Description: Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
Study NCT02110602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet low in amino acid levels
Description: Meals will be prepared in the Clinical Research Center Metabolism \& Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
Study NCT05090176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: povidone-soaked suture
Description: suture soak with povidone solution for 3 mins
Study NCT05090176 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ordinary suture
Description: suture no need to soak with povidone solution
Study NCT00849316 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
Study NCT00754221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Description: Once a day, oral treatment, of 4, 6, 8 or 10 mg
Study NCT04143308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous training of walking and cognitive group
Description: Device:~1. SWATCH system (App \& controller)~2. Wearable technology Fitness wristband \& APP
Study NCT04143308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive training group
Description: Device:~1. SWATCH system (App)~2. Wearable technology Fitness wristband \& APP
Study NCT04143308 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual group
Description: Keep treatment as usual
Study NCT01957670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrima medical Prototypes
Study NCT04545970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Facial cleanser
Description: Facial cleanser to be used by study participants
Study NCT04545970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Facial cleanser
Description: Facial cleanser to be used by study participants
Study NCT04545970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Facial moisturizer
Description: Bland moisturizer to be used by study participants after serum in the evening.
Study NCT04545970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Facial moisturizer
Description: Bland moisturizer to be used by study participants after serum in the evening.
Study NCT04545970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of serum in the morning.
Study NCT04545970 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen to be applied after application of serum in the morning.
Study NCT04544215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dosage 1 of MPCs-derived exosomes
Description: 7 times aerosol inhalation of MPCs-derived exosomes (8.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
Study NCT04544215 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dosage 2 of MPCs-derived exosomes
Description: 7 times aerosol inhalation of MPCs-derived exosomes (16.0\*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7).
Study NCT04544215 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: No MPCs-derived exosomes
Description: No aerosol inhalation of MPCs-derived exosomes
Study NCT01357811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eliglustat; digoxin
Description: repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
Study NCT01357811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: digoxin
Description: oral 0.25mg dose of digoxin (single dose) on Day 1
Study NCT02369081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
Study NCT02369081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
Study NCT02369081 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
Study NCT02369081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment for 12 weeks.
Study NCT06190457 — intervention group
Intervention type: OTHER
Intervention: intrathecal rituximab
Description: All children were treated with a modified NHL-BFM95 regimen for children NHL with the addition of rituximab, both intravenous and intrathecal, and rituximab intrathecal infusion is scheduled to be used simultaneously with rituximab intravenous drip. rituximab intrathecal doses are 10 mg, 15 mg, and 20 mg in increments every 3 weeks. rituximab intrathecal injection does not use methotrexate or/and cytarabine intrathecaline chemotherapy.
Study NCT02680353 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral superficial cervical plexus block
Description: A kind of anesthetic nerve block type performed to block the nerve function temporarily by administrating local anesthetics through the trajectory of the nerve.
Study NCT01112709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCT-based Resistance Training exercise program
Description: Two supervised RT sessions per week for the first 3 months, then a self-monitored RT phase for the remainder of the study, with primarily Internet-based contact.
Study NCT01112709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intervention with minimal contact
Description: This is the control condition for comparison; the approach will be identical to the experimental condition, but without the theoretical components (skills to increase self efficacy for RT, self regulation for RT). Contact with the study staff will be reduced from that received by the experimental group.
Study NCT00741819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled treprostinil
Study NCT00948220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a and ribavirin
Description: standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
Study NCT02930980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Software loaded on Micra device
Description: Subject will receive an investigational software loaded on subject's Micra device
Study NCT04582123 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: crossed pin configuration
Description: comparison of two crossed pin fixation methods